AstraZeneca and Francis Crick Institute sign research agreement.
M2 PHARMA-May 24, 2017-AstraZeneca and Francis Crick Institute sign research agreement
(C)2017 M2 COMMUNICATIONS
A new research agreement has been signed by the Francis Crick Institute and AstraZeneca (LON: AZN), the institute revealed on Tuesday.
Over a five-year period, researchers from AstraZeneca and the Crick will work together on early-stage research that could go on to help create new treatments and health innovations in the future.
The aim of the collaboration is to use each other's expertise to stimulate and accelerate basic research into the understanding of human health across a range of cancers, cardiovascular and respiratory diseases.
A research fund will be established as a result of the open research agreement. The fund will include contributions from AstraZeneca, Cancer Research UK, as well as money from an existing Medical Research Council translational research award to the Crick. The research fund will be used to support Crick researchers in projects at an early 'pre-competitive' stage of development.
Under the terms of the agreement, Crick researchers will have access to AstraZeneca compounds, as well as a range of technology platforms.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 24, 2017|
|Previous Article:||Brexit spells trouble for British biotech firms.|
|Next Article:||Igenica Biotherapeutics' immuno-oncology assets acquired by Pierre Fabre.|